DANIEL ERNESTO
CASTELLANO GAUNA
Profesor asociado de Ciencias de la Salud
Centre Hospitalier de l’Université de Montréal
Montreal, CanadáPublicaciones en colaboración con investigadores/as de Centre Hospitalier de l’Université de Montréal (7)
2023
-
Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022
European Urology
-
Management of patients with advanced prostate cancer—metastatic and/or castration-resistant prostate cancer: report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022
European Journal of Cancer
2022
-
Nivolumab plus docetaxel in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer: results from the phase II CheckMate 9KD trial
European Journal of Cancer, Vol. 160, pp. 61-71
-
Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trial
Journal for immunotherapy of cancer, Vol. 10, Núm. 8
-
Pain and health-related quality of life with olaparib versus physician's choice of next-generation hormonal drug in patients with metastatic castration-resistant prostate cancer with homologous recombination repair gene alterations (PROfound): an open-label, randomised, phase 3 trial
The Lancet Oncology, Vol. 23, Núm. 3, pp. 393-405
2018
2017
-
Cabazitaxel versus docetaxel as first-line therapy for patients with metastatic castration-resistant prostate cancer: A randomized phase III trial - FIRSTANA
Journal of Clinical Oncology, Vol. 35, Núm. 28, pp. 3189-3197